Table 3.
Effect of evolocumab on markers of atheroma burden stratified by baseline hsCRP.
| hsCRP |
P value | |||
|---|---|---|---|---|
| <1 mg/L [n = 132] | 1–3 mg/L [n = 170] | >3 mg/L [n = 111] | ||
| PAV | ||||
| - baseline, % | 37.2 ± 8.2 | 36.9 ± 9.0 | 34.9 ± 8.8 | 0.10 |
| - LSM, % | −0.87 (−1.46,-0.27) | −0.84 (−1.38,-0.29) | −1.22 (−1.85,-0.58) | 0.46 |
| - p value | 0.005 | 0.003 | <0.001 | |
| TAV | ||||
| - baseline, mm3 | 180.4 (129.2,257.2) | 174.2 (131.1,240.0) | 163.7 (124.5,214.6) | 0.08 |
| - LSM, mm3 | −6.18 (−10.3,-2.1) | −5.46 (−9.22,-1.70) | −8.13 (−12.5,-3.76) | 0.49 |
| - p value | 0.003 | 0.005 | <0.001 | |
| ‘Regressors’ | ||||
| - PAV, % | 65.9 | 63.5 | 63.1 | 0.88 |
| - TAV, % | 62.1 | 59.4 | 63.1 | 0.80 |
LSM – least squared mean (95%CI); PAV – percentage atheroma volume, mm3 ± SD; TAV – total atheroma volume, mm3 (IQR).